We’re delighted to announce our continued commitment to revolutionise the treatment of Type 1 diabetes, by awarding £490,000 – in partnership with JDRF – to fund the next generation of immunotherapy research.

NHS England have made us aware that Cellnovo are ceasing production and operations with immediate effect. The company has gone into administration.